AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12810245
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with pioglitazone (30 mg/day) plus metformin
Trial: 12810245
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with pioglitazone (15 or 30 mg/day) plus sulfonylurea
Trial: 9148020
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of anti-neutrophil cytoplasmic antibodies (ANCA)
Trial: 9148020
Drug: Absorption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorption of sera with actin
Trial: 8342184
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (ASA) 75 mg/d for 6 months
Trial: 3538957
Drug: Monitored group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitored group (theophylline dosages adjusted daily based on estimated clearance)
Trial: 27462118
Drug: Intravenous albumin
RxNorm normalized name: albumin human, USP Injection [Albuminar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous albumin 25% at 2 g/kg
Trial: 24766978
Drug: Ezetimibe prescriptions
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe prescriptions in the US
Trial: 24766978
Drug: Ezetimibe prescriptions
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe prescriptions in Canada
Trial: 24365167
Drug: 6% HES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% HES 130/0.4 plus lactated Ringer's solution
Trial: 24365167
Drug: lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lactated Ringer's solution
Trial: 18180340
Drug: Docosahexaenoic acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid (400 mg/d)
Trial: 12608556
Drug: Blood flow
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood flow at 200 ml/min
Trial: 12608556
Drug: Blood flow
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood flow at 250 ml/min
Trial: 12608556
Drug: Blood flow
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood flow at 300 ml/min
Trial: 8635384
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (cisplatin 50 mg/m2 or 100 mg/m2 plus 3 g/m2 ifosfamide and 6 mg/m2 mitomycin)
Trial: 30652260
Drug: Off-label topical
RxNorm normalized name: Off! Explore Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off-label topical therapies (e.g., prostaglandin analogs, polyphenols like latanoprost and procyanidin oligomers)
Trial: 26684457
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib sodium 1 mg·kg(‐1) (Group P, n = 30)
Trial: 26684457
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib sodium 1 mg·kg(‐1) (Group P)
Trial: 18974283
Drug: Teduglutide 50
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 50 mg/mL and 20 mg/mL formulations
Trial: 18974283
Drug: Teduglutide 50
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 50 mg/mL formulation
Trial: 18974283
Drug: Teduglutide 20
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 20 mg/mL formulation (1.0 mL)
Trial: 18974283
Drug: Teduglutide treatments
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide treatments
Trial: 18974283
Drug: Injection site
RxNorm normalized name: Dual Injection Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection site pain
Trial: 31663980
Drug: Transcribed list
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcribed list of six treatment recommendations
Trial: 31663980
Drug: Verbal discussion
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal discussion of six treatment recommendations
Trial: 24952869
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg/kg intraoperatively)
Trial: 20634438
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg every 48 hours)
Trial: 17178938
Drug: Ofloxacin otic
RxNorm normalized name: ofloxacin otic
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin otic drops
Trial: 17178938
Drug: Neomycin-polymyxin B
RxNorm normalized name: Dexamethasone-Neomycin-Polymyxin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin-polymyxin B otic drops
Trial: 17178938
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative otic drop prophylaxis (Control group)
Trial: 14574830
Drug: Methylphenidate 10
RxNorm normalized name: dexmethylphenidate 10.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 10 mg 3 times daily for 2 weeks
Trial: 14574830
Drug: Methylphenidate 15
RxNorm normalized name: METHYLPHENIDATE 15MG/9HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 15 mg 3 times daily for 2 weeks
Trial: 10782522
Drug: Sublingual-swallow immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual-swallow immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (D.pt.) - D. farinae (D.f) 50/50 extract, mean cumulative dose of 90,000 IR (2.2 mg of Der p 1 and 1.7 mg of Der f I) for 24 months.
Trial: 10782522
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 24 months.
Trial: 8633933
Drug: Standard cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cold topical irrigation
Trial: 1727165
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg bolus and 5.4 mg/kg/hr for 23 hours)
Trial: 1727165
Drug: Naloxone (5.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (5.4 mg/kg bolus and 4.0 mg/kg/hr for 23 hours)
Trial: 6376653
Drug: 14-valent streptococcus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-valent streptococcus pneumoniae polysaccharide vaccine
Trial: 27295927
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement with immediately loaded mandibular overdenture
Trial: 27295927
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement with immediately loaded mandibular overdenture
Trial: 25428140
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for ADHD symptoms and IPV, duration of treatment is one year with assessments at t0, 8, 16, 24, and 52 weeks.
Trial: 24341093
Drug: Cefoxitin sodium
RxNorm normalized name: Cefoxitin Sodium
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefoxitin sodium iv at 1.0 g 30 minutes before complete urodynamic examination
Trial: 10967001
Drug: No pre-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre-treatment (Control)
Trial: 20026265
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate 2 g/d
Trial: 18084691
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg daily oral DHEA supplementation for one year
Trial: 9344324
Drug: Doxorubicin-ifosfamide combination
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin-ifosfamide combination chemotherapy
Trial: 28295802
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy based on the Clark and Wells model
Trial: 21508389
Drug: CAPOX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPOX treatment (capecitabine plus oxaliplatin) with bevacizumab
Trial: 16669956
Drug: Alicaforsen enema
RxNorm normalized name: Alicaforsen
DrugBank: Alicaforsen (DB06224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alicaforsen enema (240 mg daily for 6 weeks)
Trial: 15571956
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg daily for three months followed by 1 mg daily for five years
Trial: 11256555
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (270 microg four times daily) for 2 weeks
Trial: 11256555
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after 2 weeks of inhaled albuterol
Trial: 9143863
Drug: Colchicine (1.0‐2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1.0‐2.0 mg.day‐1) for 2‐13 years
Trial: 9143863
Drug: Intravenous colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous colchicine (2 mg) infusion
Trial: 26741384
Drug: Juvéderm Ultra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juvéderm Ultra (24 mg/mL)
Trial: 26741384
Drug: Restylane (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane (20 mg/mL)
Trial: 25335781
Drug: Anthocyanin intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanin intake (271 mg and 7.11 mg C3g eq) in S2 trial
Trial: 25335781
Drug: Anthocyanin intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanin intake (346 mg C3g eq) in L1 trial
Trial: 10965103
Drug: Cefpirome (CPM)
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome (CPM) 2 g i.v. every 12 h
Trial: 10965103
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g i.v. every 8 h
Trial: 8648203
Drug: Schwarz (SW9)
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz (SW9) strain of measles vaccine
Trial: 8648203
Drug: Schwarz (SW6)
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz (SW6) strain of measles vaccine
Trial: 8648203
Drug: Edmonston-Zagreb (EZ)
RxNorm normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb (EZ) strain of measles vaccine
Trial: 6308068
Drug: Enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate (20 mg b.i.d.)
Trial: 6308068
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg b.i.d.)
Trial: 6308068
Drug: Enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate (20 mg b.i.d.) and Hydrochlorothiazide (25 mg b.i.d.) in combination
Trial: 30287097
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline Solution
Trial: 15133294
Drug: Radon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radon therapy
Trial: 12575588
Drug: TWP combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TWP combined with MT (TWP 10 mg orally, 3 times a day; MT 7.5 mg orally once a week)
Trial: 12575588
Drug: MT (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT (15 mg orally, once every week)
Trial: 9782544
Drug: Anti-gravity suit
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-gravity suit (anti-G)
Trial: 30554600
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream twice daily
Trial: 30554600
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream once daily
Trial: 30554600
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream
Trial: 26628383
Drug: Warfarin (n=814)
RxNorm normalized name: (-)-Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (n=814)
Trial: 23160920
Drug: Olmesartan medoxomil/amlodipine
RxNorm normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (single dose)
Trial: 23160920
Drug: Olmesartan medoxomil/amlodipine
RxNorm normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (multiple doses)
Trial: 23160920
Drug: Olmesartan medoxomil/amlodipine
RxNorm normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (both single and multiple doses)
Trial: 15776832
Drug: terazosine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terazosine (5 mg/day, n = 29)
Trial: 10512904
Drug: Aptiganel HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aptiganel HCl (4.5 mg bolus followed by 0.75 mg/h infusion for 12 hours)
Trial: 10512904
Drug: Aptiganel HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aptiganel HCl (6 mg bolus followed by 1 mg/h infusion)
Trial: 10512904
Drug: Aptiganel HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aptiganel HCl (7.5 mg bolus)
Trial: 10512904
Drug: Aptiganel HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aptiganel HCl (3 mg, 4.5 mg, 6 mg, 7.5 mg bolus doses)
Trial: 7860749
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg draflazine
Trial: 7860749
Drug: Adenosine dosages
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine dosages (0.15, 0.5, 1.5, 5, 15, and 50 micrograms/100 ml forearm per min)
Trial: 1781051
Drug: Gitadyl (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gitadyl (a herbal medicine containing 110 mg fever few, 90 mg American aspen, and 60 mg milfoil)
Trial: 1781051
Drug: Ibuprofen (Ibumetin)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (Ibumetin) 1,200 mg
Trial: 31825471
Drug: Sacubitril/valsartan (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (titrated to 97/103 mg twice daily)
Trial: 31825471
Drug: Enalapril (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (titrated to target dose, 10 mg twice daily)
Trial: 27151378
Drug: Low-dose CD34+
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CD34+ stem cells (1×10^5 CD34/kg body weight)
Trial: 27151378
Drug: High-dose CD34+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CD34+ stem cells (5×10^5 CD34/kg)
Trial: 27151378
Drug: Low-dose CD34+
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CD34+ stem cells
Trial: 27151378
Drug: High-dose CD34+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CD34+ stem cells
Trial: 19512866
Drug: Nefopam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (100 ng/ml) and Clonidine (2.5 microg/kg)
Trial: 19512866
Drug: Nefopam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (100 ng/ml) and Alfentanil (150 ng/ml)
Trial: 12324985
Drug: New patterns
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New patterns of insulin use
Trial: 29178731
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush with tapered bristles (Oral‐B Super Thin Indicator toothbrush, OM159)
Trial: 29178731
Drug: Marketed control
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed control toothbrush (Study 1: Oral‐B Complete Clean & Sensitive toothbrush; Study 2: Crest Pro‐Health Complete 7 Brush 35 toothbrush)
Trial: 23714676
Drug: Sham infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham infusions (n = 18)
Trial: 16998290
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg i.v. initially and 1 mg i.v. every 4 hours for 3 days)
Trial: 16998290
Drug: Octreotide (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (continuous infusion of 25 microgram/h for 5 days)
Trial: 11074150
Drug: Nasal nicotine
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal nicotine spray (1-2mg)
Trial: 11074150
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo spray of oleoresin of pepper
Trial: 8513038
Drug: Fenfluramine (FF)
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (FF) 60 mg orally
Trial: 26860800
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng (3.0 g/day)
Trial: 23156978
Drug: Nebulized terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized terbinafine solution made with crushed tablet
Trial: 23156978
Drug: Nebulized terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized terbinafine solution made with raw drug powder
Trial: 19029416
Drug: Structured QOL
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured QOL diary (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and the related lung cancer module LC13) completed weekly for 16 weeks
Trial: 17545356
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone dosage of 0.11 IU/kg body weight per day
Trial: 17545356
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone dosage of 0.21 IU/kg body weight per day
Trial: 11000734
Drug: ALM subgroup
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALM subgroup (lansoprazole + amoxicillin + metronidazole)
Trial: 11000734
Drug: ALC subgroup
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALC subgroup (lansoprazole + amoxicillin + clarithromycin)
Trial: 8834030
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg/day) and ursodeoxycholic acid
Trial: 1468087
Drug: Magnesium chloride
RxNorm normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium chloride solution
Trial: 1468087
Drug: Slow-release magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release magnesium chloride tablets
Trial: 1468087
Drug: Magnesium gluconate
RxNorm normalized name: Magnesium Gluconate
DrugBank: Magnesium gluconate (DB13749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium gluconate tablets